Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492673 · ClinicalTrials.gov registry record · Phase 2
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
A Phase 2 study of Sarcoma and Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 7
- Study locations
NCT01492673 is a Phase 2 study of Sarcoma and Neuroblastoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT01492673, a Phase 2 study of Sarcoma and Neuroblastoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer. The medications, cyclophosphamide and topotecan, are standard drugs often used together for the treatment of cancer in children with either Ewing's sarcoma or neuroblastoma. Bevacizumab is an experimental drug called an antibody that targets a protein important in the growth of cancer cells called vascular endothelial growth factor (VEGF). VEGF is made by tumor and other surrounding cells to help make blood vessels needed for the growth and spread of cancer cells in the body. The way that bevacizumab works is to stop the cancer cells from making their own blood supply, causing the tumor to stop growing bigger or from spreading. In adult clinical trials, bevacizumab has shown promising anti-cancer activity in patients with cancer of the colon/rectum (colorectal) and breast. It has been approved by the Food and Drug Administration (FDA) for use in patients with colorectal cancer but not in cancers found in children. Bevacizumab has been tested in early clinical studies in children and has been shown to be safe. Other goals of this study will include research tests designed to test the following changes in the patient or their cancer: to see how the body handles and breaks down bevacizumab (pharmacokinetics), to look at changes in proteins in the blood that may affect the way the cancer responds to the combination (angiogenic profile, angiogenesis associated serum biomarkers), to look at changes in genes that may affect how the cancer responds to treatment with this combination of medications (metabolic signature), and to monitor the effects of changes in the way the body grows and develops before and after bevacizumab is given.
Conditions Studied
Interventions
- DRUG Cyclophosphamide, Topotecan, and Bevacizumab
Study Locations (7)
Arizona
- Phoenix Children'S Hospital - Phoenix
Colorado
- University of Colorado Health Sciences Center and The Children's Hospital - Denver
Florida
- MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children - Orlando
Missouri
- Children's Mercy Hospital & Clinics - Kansas City
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Pennsylvania State University College of Medicine - Hershey
Alberta
- Alberta Children'S Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-12 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492673
The ClinicalTrials.gov registry entry for NCT01492673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Cyclophosphamide, Topotecan, and Bevacizumab is the first listed.
NCT01492673 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT01492673 about?
NCT01492673 is a clinical study titled "Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma". The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer. The medications, cyclophosphamide and topotecan, are standard drugs often used together for the treatme...
What is the current status of trial NCT01492673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2011-12. Estimated completion is 2018-10-31.
What conditions does trial NCT01492673 study?
This clinical trial studies the following conditions: Sarcoma, Neuroblastoma.
What interventions are being tested in trial NCT01492673?
The interventions under investigation include: Cyclophosphamide, Topotecan, and Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01492673?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01492673 being conducted?
This trial has 7 study locations across Arizona, Colorado, Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.